(Bloomberg) -- Two of AstraZeneca Plc’s best-selling medicines showed advances in lethal diseases.
Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.
Imfinzi is one of a number of new products that have made AstraZeneca into a redoubt of cancer treatments -- challenging established rivals like Roche Holding AG -- and sent the shares rising almost 40% in the past two years.
The U.K. drugmaker also said its diabetes drug Farxiga showed “overwhelming efficacy” earlier than expected in a clinical trial on patients with chronic kidney disease, leading Astra to stop it early.
©2020 Bloomberg L.P.
Advertisement